A Phase 1, 2-Part, Open-label Study to Evaluate Relative Bioavailability of Alternate Formulations of BMS-986460 in Healthy Adult Male Participants (Part 1), and a Single Ascending Dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of BMS-986460 in Healthy Adult Male Participants (Part 2)
Latest Information Update: 23 Jan 2026
At a glance
- Drugs BMS 986460 (Primary)
- Indications Prostate cancer
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Bristol-Myers Squibb
Most Recent Events
- 20 Jan 2026 Status changed from recruiting to completed.
- 17 Nov 2025 Planned End Date changed from 29 Oct 2025 to 17 Dec 2025.
- 17 Nov 2025 Planned primary completion date changed from 29 Oct 2025 to 17 Dec 2025.